ApoCIII inhibition by volanesorsen reduced plasma concentrations of apoCII, apoCIII, and TG, without affecting concentrations of apoB100.149,159,160 Whether targeting of apoCIII in patients with elevated concentrations of TRLs will reduce risk of CVD is subject of ongoing studies, but a recent report on the use of volanesorsen in individuals with familial chylomicronaemia syndrome, a rare genetic disorder characterized by marked chylomicronaemia leading to pancreatitis, indicated a significant reduction in disease burden.161. Here, APOC2 is linked to pancreatitis.